Ann: OLE Study update reveals impressive Survival Data, page-72

All in good time JJ.

-Great ph1 / 2 results
-Orphan Drug Designation
-Knock me down with a feather OLE entry results

They have much more to tell I reckon.

This OLE announcement comes just days after the MT return announcement which suggests they are sparingly spacing out the news because they have plenty to tell!

Once they clear the backlog of info, then and only then will we get the funding details. It is moving at pace so it won’t be long, I reckon a couple of weeks.

So let’s focus on lifting the share price rather than grinding teeth on a funding gap that we know is needing to be resolved and where we have a new and energetic team focused on doing right by shareholders.

If those results don’t turn big pharma heads, well, makes you wonder what would!